Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesGlutamate-based antidepressants: 20 years on
Trends in Pharmacological Sciences, 10/29/09
Skolnick P et al. – The authors describe evidence that glutamate–based therapies might represent an effective alternative to biogenic–amine–based agents for depression and provide perspectives on the development of these agents.
Related Articles
The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets, 10/30/09
Relevance Score: 64%
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes
Journal of Pharmacology and Experimental Therapeutics, 10/26/09
Relevance Score: 64%
Early induction of CREB activation and CREB-regulating signalling by antidepressants
International Journal of Neuropsychopharmacology, 10/21/09
Relevance Score: 64%
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
Expert Opinion on Investigational Drugs, 10/02/09
Relevance Score: 64%
Use of Antidepressants for Management of Hot Flashes
Pharmacotherapy, 10/27/09
Relevance Score: 63%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy
Journal of Neuro-Oncology, 12/04/09
Health related quality of life in early Parkinson's disease: Impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort
Parkinsonism & Related Disorders, 12/04/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/04/09
Sponsor
Article Search
Sponsor